Topline data were announced from a phase 3 trial evaluating secukinumab in patients with polymyalgia rheumatica.

Learn about polymyalgia rheumatica, temporal arteritis, their symptoms, causes, and treatment options to manage pain, ...

Novartis said that its immunology drug Cosentyx met the primary target and all secondary ones in a late-stage trial for the treatment of patients with inflammatory disease polymyalgia rheumatica.

Novartis today announced that Cosentyx® (secukinumab) met the primary endpoint and all secondary endpoints in the Phase III REPLENISH trial 1. Cosentyx demonstrated statistically significant and ...

In patients with polymyalgia rheumatica with relapse during glucocorticoid tapering, interleukin-6 receptor antagonist sarilumab increased disease remission and reduced glucocorticoid exposure at 1 ...

Explore causes, symptoms and diagnosis of Giant Cell Arteritis and Temporal Arteritis including headache, vision loss and jaw ...